References

1. Fraser CL, Arieff AI: Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997;102:67-77

2. Griggs RC: Treatment and Prevention of Electrolyte and Acid Base Disorders. Course 145, Internal Medicine for the Neurologist. 46th Annual Meeting of the American Academy of Neurology, Washington, D. C., 1994, pp 1-48.

3. Votey SR, Peters AL, Hoffman JR. Disorders of water metabolism: Hyponatremia and hypernatremia. Emerg Med Clin 1989;7:749-769

4. Robertson GL, Aycinena P, Zerbe R: Neurogenic disorders of osmo-regulation. Am J Med 1982;72:339-353

5. Anderson RJ: Hospital-associated hyponatremia. Kidney Int 1986;29:1237-1247

6. Anderson RJ, Chung HM, Kluge R, Schrier RW: Hyponatremia: A prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164-16i

7. Arieff A: Treatment of acid-base and electrolyte disorders. Internal Medicine for the Neurologist. 44th Annual Meeting of the American Academy of Neurology, San Diego, CA, ■ 992.

8. Donaldson JO: Neurology of Pregnancy, 2nd ed. Philadelphia, W.B. Saunders, 198 9.

9. Riggs JE: Neurological manifestations of electrolyte disorders. In Aminoff MJ (ed): Neurology and General Medicine, 2nd ed. New York, Churchill Livingstone, 1995, pp 321-3 31.

10. DeFronzo RA, Arieff AI: Hyponatremia: Pathophysiology and treatment. In Arieff AI, DeFronzo RA (eds): Fluid, Electrolyte, and Acid-base Disorders, 2nd ed. New York, Churchill Livingstone, 1995, pp 255-3 03.

11. Sarnaik AP, Meert K, Hackbarth R, Fleischmann L: Management of hyponatremic seizures in children with hypertonic saline: A safe and effective strategy. Crit Care Med 1991;19:758-762

12. Ayus JC, Krothapalli RK, Arieff AI: Treatment of symptomatic hyponatremia and its relation to brain damage: A prospective study. n Engl J Med 1987;317:1190-1195

13. Riggs JE, Schochet SS Jr: Osmotic stress, osmotic myelinolysis, and oligodendrocyte topography. Arch Pathol Lab Med 1989;113:1386-138i

14. Adams RD, Victor M, Mancall EL: Central pontine myelinolysis: A hitherto undescribed disease occurring in alcoholic and malnourished patients. Arch Neurol Psychiatry 1959;81:154-172

15. Paguirigan A, Lefken EB: Central pontine myelinolysis. Neurology 1969;19:1007-1011

16. Leslie KO, Robertson AS, Norenberg MD: Central pontine myelinolysis: An osmotic gradient pathogenesis. J Neuropathol Exp Neurol 1980;39:370

17. Sterns RH, Riggs JE, Schochet SS Jr: Osmotic demyelination syndrome following correction of hyponatremia. n Engl J Med 1986;314:1535-1542

18. Tien R, Arieff AI, Kucharczyk W, et al: Hyponatremic encephalopathy: Is central pontine myelinolysis a component? Am J Med 1992;92:513-522

19. Ayus JC, Arieff AI: Pulmonary complications of hyponatremic encephalopathy: Noncardiogenic pulmonary edema and hypercapnic respiratory failure. Chest 1995;107:517-521

20. Laureno R, Karp BI: Myelinolysis after correction of hyponatremia. Ann Intern Med 1997;126:57-62

21. Andrews BT: Fluid and electrolyte disorders in neurosurgical intensive care. Neurosurg Clin 1994;5:707-723

22. Darby JM, Nelson PB: Fluid, electrolyte, and acid-base balance in neurosurgical intensive care. In Andrews BT (ed): Neurosurgical Intensive Care. New York, McGraw-Hill, 1993, pp 133-16 2.

23. Cserr HF, dePasquale M, Patlak CS: Volume regulatory influx of electrolytes from plasma to brain during acute hyperosmolality. Am J Physiol 1987;253:530-537

24. Phillips PA, Rolls BJ, Ledingham JG, et al: Reduced thirst after water deprivation in healthy elderly men. n Engl J Med 1984; 311:753-759

25. Kliman B: Metabolic derangements. In Ropper AH, Kennedy SK (eds): Neurological and Neurosurgical Intensive Care, 2nd ed. Aspen, Rockville, 1988, pp 119-128.

26. Morris-Jones PH, Houston IB, Evans RC: Prognosis of the neurological complications of acute hypernatremia. Lancet 1967;2:1385-1389

27. Zull DN: Disorders of potassium metabolism. Emerg Med Clin 1989;7:771-794

28. Gabow PA, Peterson LN: Disorders of potassium metabolism. In Schrier RW (ed): Renal and Electrolyte Disorders, 3rd ed. Boston, Little, Brown, and Company, 1986, pp 207-2 9.

29. Pestana C: Fluids and Electrolytes in the Surgical Patient, 3rd ed. Baltimore, Williams & Wilkins, 1985, pp 3-1 13.

30. Lee KS, Powell BL, Adams PL: Focal neurological signs associated with hyperkalemia. South Med J 1984;77:792-793

31. Olinger ML: Disorders of calcium and magnesium metabolism. Emerg Med Clin 1989;7:795-822

32. Zaloga GP, Chernow B, Cook D, et al: The importance of measured serum ionized calcium levels in critically ill patients. Crit Care Med 1984;12:236

33. Zaloga GP, Wilkens R, Tourville J, et al: A simple method for determining physiologically active calcium and magnesium concentrations in critically ill patients. Crit Care Med 1987;15:813-816

34. Spiegel AM: The parathyroid glands, hypercalcemia, and hypocalcemia. In Bennett JC, Plum F (eds): Cecil Textbook of Medicine, 20th ed. Philadelphia, W.B. Saunders, 1995, pp 1364-13 3.

35. Hess LW, Morrison JC, Hess DB: General medical disorders during pregnancy. In DeCherney AH, Pernoll ML (eds): Current Obstetrics and Gynecologic Diagnosis and Treatment, 8th ed. Norwalk, CT, Appleton and Lange, 1994, pp 468-492

36. Fishman RA: Neurologic manifestations of magnesium metabolism. Course 211, Neurologic Manifestations of Electrolyte Disorders. 45th Annual Meeting of the American Academy of Neurology, New York, 1993, p p 1-5.

37. Agus ZS, Wasserstein A, Goldfarb S: Disorders of calcium and magnesium homeostasis. Am J Med 1982;72:473-488

38. Koeze TH, Klingon GH: Acquired toxoplasmosis: Case with focal neurologic manifestations. Arch Neurol 1964;11:191-197

39. Lipsky MS: Hypercalcemia. In Rakel RE (ed): Saunders Manual of Medical Practice. Philadelphia, W.B. Saunders, 1996, pp 663-66 4.

40. Dent DM, Miller JL, Klaff L, et al: The incidence and causes of hypercalcemia. Postgrad Med J 1987;63:745-750

41. Elin RJ: Assessment of magnesium status. Clin Chem 1987;33:1965-1970

42. Tosiello L: Hypomagnesemia and diabetes mellitus. Arch Intern Med 1996;156:1143-114t

43. Shils ME: Experimental human magnesium depletion. Medicine (Baltimore) 1969;48:61-81

44. Alfrey AC: Disorders of magnesium metabolism. In Bennett JC, Plum F (eds): Cecil Textbook of Medicine, 20th ed. Philadelphia, W.B. Saunders, 1995, pp 1137-1138.

45. McLean RM: Magnesium and its therapeutic uses: A review. Am J Med 1994;96:63-76

46. Pernoll ML, Taylor CM: Normal pregnancy and prenatal care. In DeChaney AH, Pernoll ML (eds): Current Obstetrics and Gynecologic Diagnosis and Treatment, 8th ed. Norwalk, Appleton and Lange, 1994, pp 183- 01.

47. Chernow B, Smith J, Rainey TG, et al: Hypomagnesemia: Implications for the critical care specialist. Crit Care Med 1982;10:193

48. Fishman RA: Neurological aspects of magnesium metabolism. Arch Neurol 1965;12:562-56 9.

49. Riggs JE: Cardioskeletal mitochondrial myopathy associated with chronic magnesium deficiency. Neurology 1992; 42:128-130

50. Swift TR: Weakness from magnesium-containing cathartics: Electrophysiologic studies. Muscle Nerve 1979;2:95-298

51. Reinhart RA: Magnesium metabolism: A review with special reference to the relationship between intracellular content and serum levels. Arch Intern Med 1988; 148:2415-2420

52. Somjen G, Hilmy M, Stephen CR: Failure to anesthetize human subjects by intravenous administration of magnesium sulfate. J Pharmacol Exp Ther 1968;154:652-659

53. Pulsinelli WA, Cooper AJL: Metabolic encephalopathies and coma. In Siegel G, Agranoff B, Albers RW, Molinoff P (eds): Basic Neurochemistry, 4th ed. New York, Raven Press, 1989, pp 765-78 1.

54. Bleck TP: Metabolic encephalopathies. In Weiner WJ (ed): Emergent and Urgent Neurology. Philadelphia, J.B. Lippincott, 1992, pp 27-5 7.

55. Jozefowicz RF: Neurolgic manifestations of pulmonary disease. Neurol Clin 1989;7:605-610

56. Simon RP, Aminoff MJ, Greenberg DA: Disorders of Cognitive Function: Approach to Diagnosis and Acute Confusional States. In Simon rp, Aminoff mj, Greenberg da (eds): Clinical Neurology. Norwalk, ct, Appleton and Lange, 1989, pp 1-40

57. Bennett DA, Bleck TP: Diagnosis and treatment of neuromuscular causes of acute respiratory failure. Clin Neuropharmacol 1988;11:303-347

58. Bates DV: The respiratory muscles and their disorders. In Bates DV (ed): Respiratory Function in Disease, 3rd ed. Philadelphia, W.B. Saunders, 1989, pp 369-3*1.

59. Adams RD, Victor M: The acquired metabolic disorders of the nervous system. In Adams RD, Victor M (eds): Principles of Neurology, 5th ed. New York, McGraw-Hill, 1993, pp 877-90 2.

60. Aminoff MJ: Neurological complications of systemic disease in adults. In Bradley WG, Daroff RB, et al (eds): Neurology in Clinical Practice, 2nd ed. Boston, Butterworth-Heinemann, 1996, pp 905-9 30.

61. Myers RAM, Snyder SK, Emhoff TA: Subacute sequelae of carbon monoxide poisoning. Ann Emerg Med 1985;14:1163-1167

62. Gibson GE: Hypoxia. In McCandless DW: Cerebral Energy Metabolism and Metabolic Encephalopathy. New York, Plenum, 1985, pp 43- 8.

63. Gibson GE, Peterson C: Decreases in the release of acetylcholine in vitro with low oxygen. Biochem Pharmacol 1982;31:111-m

64. Lance JW, Adams RD: The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 1963;86:111-136

65. Fahn S: Posthypoxic action myoclonus: Literature review update. Adv Neurol 1986;43:157-169

66. Choi IS: Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol 1983;40:433-435

67. Dooling EC, Richardson EP Jr: Delayed encephalopathy after strangling. Arch Neurol 1976;33:196-199

68. Weiner WJ, Lang AE (eds): Movement disorders: A comprehensive survey. New York, Futura, 198 .

69. Fenichel GM: Paraplegia and quadriplegia. In Fenichel GM (ed): Clinical Pediatric Neurology: A Signs and Symptoms Approach. Philadelphia, W.B. Saunders, 1988, pp 263-2 78.

70. Gardner WN: The pathophysiology of hyperventilation disorders. Chest 1996;109:516-534

71. Saltzman HA, Heyman A, Sieker HO: Correlation of clinical and physiologic manifestations of sustained hyperventilation. n Engl J Med 1963;268:1431-1436

72. Mountz JM, Modell JG, Wilson MW, et al: Positron emission tomographic evaluation of cerebral blood flow during state anxiety in simple phobia. Arch Gen Psychiatry 1989;46:501-504

73. Mitchell JM: Thyroid disease in the emergency department: Thyroid function tests and hypothyroidism and myxedema coma. Emerg Med Clin 1989;7:885-902

74. Mazzaferri EL: Adult hypothyroidism: I. Manifestations and clinical presentation. Postgrad Med 1986;79:64-72

75. Myers L, Hays J: Myxedema coma. Crit Care Clin 1991;7:43-56

76. Kissel JT: Endocrine Myopathies. Update on Neuromuscular Disease. Course 423 of the aan Annual Meeting, Washington, d.c., 1994, pp 34-55.

77. Layzer RB: Neuromuscular manifestations of endocrine disease. In Becker KL, Bilezikian JP, Bremner WJ, et al (eds): Principles and Practice of Endocrinology and Metabolism, 2nd ed. Philadelphia, J.B. Lippincott, 1995, pp 1762-' 770.

78. Kaminski HJ, Ruff RL: Neurologic complications of endocrine diseases. Neurol Clin 1989;7:489-50i

79. Bagchi N, Brown TR, Parish RF: Thyroid function in adults over age 55 years: A study in an urban US community. Arch Intern Med 1990;150:785-787

80. Burrow GN: The thyroid gland and reproduction. In Yen SSC, Jaffe RB (eds): Reproductive Endocrinology, 2nd ed. Philadelphia, W.B. Saunders, 1986, pp 424-4 0.

81. Abend WK, Tyler HR: Thyroid disease and the nervous system. In Aminoff MJ (ed): Neurology and General Medicine, 2nd ed. New York, Churchill Livingstone, 1995, pp 333-3 17.

82. DeLong GR, Adams RD: The neuromuscular system and brain in hypothyroidism. In Braverman LE, Litiger RD (eds): Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, 6th ed. New York, J.B. Lippincott, 1991, pp 1027-1039.

83. Earll JM, Kolb FO: Facial paralysis occurring with hypothyroidism: A report of two cases. Calif Med 1967;106:56-58

84. Van't Hoff W, Stuart DW: Deafness in myxedema. q j Med 1979;48:361-367

85. Kurupath R, Ahlskog E, Garrity JA, Kurland LT: Idiopathic intracranial hypertension. Mayo Clin Proc 1994;69:169-180

86. River Y, Zelig O: Triphasic waves in myxedema coma. Clin Electroencephalogr 1993; 24:146-150

87. Arlot S, Debussche X, Lalaw JD, et al: Myxedema coma: Responses of thyroid hormone with oral and intravenous high-dose l-thyroxine treatment. Intens Care Med 1991;19:16-18

88. Tsitouras PD: Myxedema coma. Clin Geriatric Med 1995;11:251-251

89. DeLong GR, Adams RD: The neuromuscular system and brain in thyrotoxicosis. In Braverman LE, Litiger RD (eds): Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, 6th ed. New York, J.B. Lippincott, 1991, pp 793-802.

90. Shahar E, Shapiro MS, Shenkman L: Hyperthyroid-induced chorea: Case report and review of the literature. Isr J Med Sci 1988;24:264-266

91. Feibel JH, Campa JF: Thyrotoxic neuropathy (Basedow's paraplegia). J Neurol Neurosurg Psychiatry 1976;39:491-497

92. Kammer GM, Hamilton CR: Acute bulbar muscle dysfunction and hyperthyroidism: A study of four cases and review of the literature. Am J Med 1974;56:464-470

93. Gorman CA: Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc 1983;58:515-519

94. Feinberg WD, Underdahl LO, Eaton LM: Myasthenia gravis and myxedema. Mayo Clin Proc 1957;32:299-305

95. Gittinger JW Jr: Eye diseases. In Wyngaarden JB, Smith LH Jr (eds): Cecil Textbook of Medicine, 18th ed. Philadelphia, W.B. Saunders, 1988, pp 2289-22 99.

96. Bahn RS, Garrity JA, Gorman CA: Diagnosis and management of Graves' ophthalmopathy. J Clin Endocrin Metab 1990;71:559-563

97. Trobe JD, Glaser JS, Laflamme P: Dysthyroid optic neuropathy. Arch Ophthalmol 1978;96:1199-1209

98. Zimmerman EA: Endocrine diseases. In Rowland LP (ed): Merritt's Textbook of Neurology, 8th ed. Philadelphia, Lea and Febiger, 1989, pp 823-8 14.

99. Jatzko GR, Lisborg PH, Muller MG, et al: Recurrent nerve palsy after thyroid operations: Principal nerve identification and a literature review. Surgery 1994;115:139-144

100. Williams GH, Dluhy RG: Diseases of the adrenal cortex. In Braunwald E, Isselbacher KJ, Petersdorf RG, et al (eds): Harrison's Principles of Internal Medicine, 11th ed. New York, McGraw-Hill, 1987, pp 1753-1 74.

101. Loriaux DL. Adrenocortical insufficiency. In Becker KL, Bilezikian JP, Brenner WJ, et al (eds): Principles and Practice of Endocrinology and Metabolism, 2nd ed. Philadelphia, J.B. Lippincott, 1995, pp 682 686.

102. Rone JK: Adrenal insufficiency. In Rakel RE (ed): Saunders Manual of Medical Practice, Philadelphia, W.B. Saunders, 1996, pp 653-6 6.

103. Grinspoon SK, Biller BMK: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 1994;79:923-93:

104. Rusnak RA: Adrenal and pituitary emergencies. Emerg Med Clin 1989;7:903-925

105. Newell KA, Prinz RA, Pickleman J, et al: Pheochromocytoma multisystem crisis: A surgical emergency. Arch Surg 1988;123:956-959

106. Schipper HM, Abrams GM: Other endocrinopathies and the nervous system. In Aminoff MJ (ed): Neurology and General Medicine, 2nd ed. New York, Churchill Livingstone, 1995, pp 383-4 00.

107. Schteingart DE: Cushing syndrome. In Becker KL, Bilezikian JP, Bremner WJ, et al (eds): Principles and Practice of Endocrinology and Metabolism, 2nd ed. Philadelphia, J.B. Lippincott, 1995, pp 667 682.

108. Norton AJ: Cushing's syndrome/disease. In Rakel RE (ed): Saunders Manual of Medical Practice. Philadelphia, W.B. Saunders, 1996, pp 651-6 2.

109. Maugans TA, Coates ML: Diagnosis and treatment of acromegaly. Am Fam Phys 1995;52:207-213

110. Melmed S, Ho K, Klibanski A, et al: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-3402.

111. Molitch ME: Clinical manifestations of acromegaly. Endocrinol Metab Clin 1992;21:597-61-.

112. Grunstein RR, Ho KY, Sullivan CE: Sleep apnea in acromegaly. Ann Intern Med 1991;115:527-532

113. Lockwood AH: Toxic and Metabolic encephalopathies. In Bradley WG, Daroff RB, Fenichel GM, et al (eds): Neurology in Clinical Practice, 2nd ed. Boston, Butterworth-Heinemann, 1996, pp 1355-13 72.

114. Rother J, Schreiner A, Wentz KU, Hennerici M: Hypoglycemia presenting as basilar artery thrombosis. Stroke 1992;23:112-113

115. Lockwood AH: Hypoglycemia. In Feldmann E (ed): Current Diagnosis in Neurology. St. Louis, Mosby, 1994, pp 214-21 6.

116. Yealy DM, Wolfson AB: Hypoglycemia. Emerg Med Clin North Am 1989;7:837-84 8

117. Wass CT, Lanier WL: Glucose modulation of ischemic brain injury: Review and clinical recommendations. Mayo Clin Proc 1996;71:801-812

118. Israel RS: Diabetic ketoacidosis. Emerg Med Clin North Am 1989;7:859-87 1.

119. Podolsky S: Hyperosmolar nonketotic coma in the elderly diabetic. Med Clin North Am 1978;4:815-828

120. Pope DW, Dansky D: Hyperosmolar hyperglycemic nonketotic coma. Endo Metab Emerg 1989;7:849-857

121. Palmer SM: Diabetes mellitus. In DeChaney AH, Pernoll ML (eds): Current Obstetrics and Gynecologic Diagnosis and Treatment, 8th ed. Norwalk, CT, Appleton and Lange, 1994, pp 368- 79.

122. Hare JW, Rossini AA: Diabetic comas: The overlap concept. Hosp Pract 1979; May 95-108

123. Tarsy D, Freeman R: The nervous system and diabetes. In Kahn CR, Weir GC (eds): Joslin's Diabetes Mellitus, 13th ed. Philadelphia, Lea and Febiger, 1994, pp 794-8 16.

124. McCall AL: The impact of diabetes on the CNS. Diabetes 1992;41:557-570

125. Harati Y: Diabetes and the nervous system. Endocrinol Metab Clin North Am 1996;25:325-359.

126. Hopf HC, Gutmann L: Diabetic 3rd nerve palsy: Evidence for a mesencephalic lesion. Neurology 1990;40:1041-1045

127. Burde RM: Neuro-ophthalmic associations and complications of diabetes mellitus. Am J Ophthalmol 1992;114:498-501

128. Kissel JT, Burde RM, Klingele TG, Zeiger HE: Pupil-sparing oculomotor palsies with internal carotid-posterior communicating artery aneurysms. Ann Neurol 1983;13:149-154

129. Wilbourn AJ. Diabetic neuropathies. In Brown WF, Bolton CF (eds): Clinical Electromyography, 2nd ed. Boston, Butterworth-Heinemann, 1993, pp 477-5'5.

130. Dyck PJ, Lais A, Karnes JL, et al: Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986;19:425-429

131. Sullivan JF: The neuropathies of diabetes. Neurology 1958;8:243-249

132. Bastron JA, Thomas JE: Diabetic polyradiculopathy. Mayo Clin Proc 1981;56:725-732

133. Low PA: Diabetic autonomic neuropathy. Semin Neurol 1996;16:143-151

134. Lockwood AH: Hepatic encephalopathy and other neurological disorders associated with gastrointestinal disease. In Aminoff MJ (ed): Neurology and General Medicine, 2nd ed. New York, Churchill Livingstone, 1995, pp 247-266.

135. McDonald M, Ralph DD, Carithers RL Jr: Severe liver disease. In Shoemaker WC, Ayres SM, Grenvik A, et al (eds): Textbook of Critical Care, 3rd ed. Philadelphia, W.B. Saunders, 1995, pp 991-10 03.

136. Wolke A, Van Ness MM: Hepatic encephalopathy. In Chobanian SJ, Van Ness MM (eds): Manual of Clinical Problems in Gastroenterology. Boston, Little, Brown and Company, 19 88.

137. Butterworth RF: Hepatic encephalopathy. Neurologist 1995;1:95-104

138. Eastwood GL, Avunduk C: Fulminant hepatic failure and encephalopathy. In Eastwood GL, Avunduk C (eds): Manual of Gastroenterology: Diagnosis and Therapy. Boston, Little Brown, 1988, pp 87-3.

139. Zieve L, Mendelson DF, Goepfert M: Shunt encephalomyelopathy. II. Occurrence of permanent myelopathy. Ann Intern Med 1960;53:53-63

140. Mullen KD, Cole M. Hepatic encephalopathy. In Feldmann E (ed): Current Diagnosis in Neurology. St. Louis, Mosby, 1994, pp 221-22 6.

141. Lavoie J, Gigre JF, Pomier LG, et al: Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. jNeurochem 1987;49:692-697

142. Pujol J, Kulisevsky J, Moreno A, et al: Neurospectroscopic alterations and globus pallidus hyperintensity as related magnetic resonance markers of reversible hepatic encephalopathy. Neurology 1996;

47:1526-1530

143. Cole M, Mullen KD: Hepatic coma and portal-systemic encephalopathy. In Johnson RT, Griffin JW (eds): Current Therapy in Neurologic Disease, 4th ed. St. Louis, Mosby, 1993, pp 326-32 9.

144. Castell DO, Moore EW: Ammonia absorption from the human colon: The role of non-ionic diffusion. Gastroenterology 1971;60:33-42

145. Sushma S, Dasarathy S, Tandon RK, et al: Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 1992;16:138-144

146. Wijdicks EFM, Litchy WJ, Wiesner RH, Krom RAF: Neuromuscular complications associated with liver transplantation. Muscle Nerve 1996;19:696-700

147. Wijdicks EFM, Plevak DJ, Wiesner RH, Steers JL: Causes and outcome of seizures in liver transplant recipients. Neurology 1996;47:1523-1525

148. Tygstrup N, Ranek L: Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis 1986;6:129-137

149. O'Grady JG, Gimson AES, O'Brien CJ, et al: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192

150. Fraser CL, Arieff AI: Nervous system manifestations of renal failure. In Schrier RW, Gottschalk CW (eds): Diseases of the Kidney, 5th ed. Boston, Little, Brown, and Company, 1992, pp 2789-28 6.

151. Olsen S: The brain in uremia. Acta Psychiatr Neurol Scand Suppl 1961;156:1-128.

152. Fishman RA, Raskin NH: Experimental uremic encephalopathy: Permeability and electrolyte metabolism of brain and other tissues. Arch Neurol 1967;17:10-21

153. Cooper JD, Lazarowitz VC, Arieff AI: Neurodiagnostic abnormalities in patients with acute renal failure: Evidence for neurotoxicity of parathyroid hormone. j Clin Invest 1978;61:1448-1455

154. Mahoney CA, Arieff AI: Central and peripheral nervous system effects of chronic renal failure. KidneyInt 1983;24:170-177

155. Arieff AI, Masry SG, Barrientos A, et al: Brain water and electrolyte metabolism in uremia: Effects of slow and rapid hemodialysis. Kidney Int 1973;4:177-187

156. Posner JB, Swanson AG, Plum F: Acid-base balance in cerebrospinal fluid. Arch Neurol 1965;12:479-496

157. Arieff AI, Guisado R, Massry SG, Lazarowitz VC: Central nervous system pH in uremia and the effects of hemodialysis. j Clin Invest 1976;58:306-311

158. Lockwood AH: Neurologic complications of renal disease. Neurol Clin 1989;7:617-627

159. Goldstein DA, Feinstein EI, Chui LA, et al: The relationship between the abnormalities in electroencephalogram and blood levels of parathyroid hormone in dialysis patients. j Clin Endocrinol Metab 1980;51:130-134

160. Arieff AI, Massry SG: Calcium metabolism of brain in acute renal failure. j Clin Invest 1974;53:387-392

161. Massry SG: Current status of the role of parathyroid hormone in uremic toxicity. Contrib Nephrol 1985;49:1-11

162. Fraser CL, Sarnacki P: Parathyroid hormone mediates changes in calcium transport in uremic rat brain synaptosomes. Am j Physiol 1988;254:837-844

163. Kjellstrand CM, Solez K: Treatment of acute renal failure. In Schrier RW, Gottschalk CW (eds): Diseases of the Kidney, 5th ed. Boston, Little, Brown, and Company, 1992, pp 1371-14 '4.

164. Warnock DG: Chronic renal failure. In Bennett JC, Plum F (eds): Cecil Textbook of Medicine, 20th ed. Philadelphia, W.B. Saunders, 1996, pp 556-5 3.

165. Manis T, Friedman EA: Dialytic therapy for irreversible uremia. n Engl j Med 1979;301:1321-1328

166. Raskin NH: Neurological complications of renal failure. In Aminoff MJ (ed): Neurology and General Medicine, 2nd ed. New York, Churchill Livingstone, 1995, pp 303-3 19

167. Raskin NH: Renal disease. In Rowland LP (ed): Merritt's Textbook of Neurology, 8th ed. Philadelphia, Lea & Febiger, 1989, pp 867-8 1.

168. Biasioli S, D'Andrea G, Feriani M, et al: Uremic encephalopathy: An updating. Clin Nephrol 1986;25:57-63

169. Adams RD, Foley JM: The neurologic changes in the more common types of severe liver disease. Trans Am Neurol Assoc 1949;74:217-219

170. Tyler HR: Neurologic disorders in renal failure. Am j Med 1968; 44:734-748

171. Sagar SM. Toxic and metabolic disorders. In Samuels MA (ed): Manual of Neurologic Therapeutics, 5th ed. Boston, Little, Brown, and Company, 1995, pp 288-3'6.

172. Noda S, Ito H, Umezaki H, Minato S: Hip flexion-abduction to elicit asterixis in unresponsive patients. Ann Neurol 1985;18:96-97

173. Raskin NH, Fishman RA: Neurologic disorders in renal failure. n Engl j Med 1976;294:143-148, 204-21C

174. Tyler HR: Neurological disorders seen in renal failure. In Vinken PJ, Bruyn BW (eds): Handbook of Clinical Neurology, Vol 27: Metabolic and Deficiency Diseases of the Nervous System. Amsterdam, North-Holland, 1976, pp 321-348.

175. Nielsen VK: The peripheral nerve function in chronic renal failure: IV. An analysis of the vibratory perception threshold. Acta Med Scand 1972;191:287-296

176. Yosipovitch G, Yarnitsky D, Mermelstein V, et al. Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve 1995;18: 768-771

177. Hamalainen H, Vartiainen M, Karavanan L, Jarivilehto T: Paradoxical heat sensation during moderate cooling of the skin. Brain Res 1982;251:77-81

178. Zucchelli P, Sturani A, Zuccala A, et al: Dysfunction of the autonomic nervous system in patients with endstage renal failure. Contrib Nephrol 1985;45:69-81

179. Ropper AH: Accelerated neuropathy of renal failure. Arch Neurol 1993;50:536-539

180. Nielsen VK: The peripheral nerve function in chronic renal failure: II. Intercorrelation of clinical symptoms and signs and clinical grading of neuropathy. Acta MedScand 1971;190:113-117

181. Guilleminault C, Cetel M, Philip P: Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445

182. Hening W. Motor disturbances of sleep. Update on the Neurology of Sleep. Course 443 of the 46th Annual Meeting of the American Academy of Neurology, Washington, DC, 1994, pp 89-1'4.

183. Lazaro RP, Kirshner HS: Proximal muscle weakness in uremia. Arch Neurol 1980;37:555-558

184. Gilmore RL: Seizures associated with nonneurologic medical conditions. In Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice. Philadelphia, Lea & Febiger, 1993, pp 667-6 77.

185. Martin BK: Potential effect of the plasma proteins on drug distribution. Nature 1965;207:274-276

186. Campion DS: Decreased drug binding by serum albumin during renal failure. Toxicol Appl Pharmacol 1973;25:391-397.

187. Nandedkar AKN, Williamson R, Kutt H, et al: A comparison of plasma phenytoin level determination by EMIT and gas-liquid chromatography in patients with renal insufficiency. Ther Drug Monit 1980;2:427-430.

188. Odar-Cederlof I, Borga O: Kinetics of diphenylhydantoin in uremic patients: Consequences of decreased plasma protein binding. Eur J Clin Pharmacol 1974; 7:31-37

189. Burgess ED, Friel PN, Blair AD, Raisys VA: Serum phenytoin concentrations in uremia. Ann Intern Med 1981;94:59-60

190. Letteri JM, Mellk H, Louis S, et al: Diphenylhydantoin metabolism in uremia. n Engl J Med 1971;285:648-652

191. Borga O, Hoppel C, Odar-Cederlof I, Garle M: Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure. Clin Pharmacol Ther 1979;26:306-31■.

192. Bolton CF, Baltzan MA, Baltzan RB: Effects of renal transplantation on uremic neuropathy. n Engl J Med 1971;284:1170-1175

193. Nielsen VK: The peripheral nerve function in chronic renal failure: VIII. Recovery after renal transplantation: Clinical aspects. Acta Med Scand 1974;195:163-170

194. Oh SJ, Clements RS Jr, Lee YW, Diethelm AG: Rapid improvement in nerve conduction velocity following renal transplantation. Ann Neurol 1978;4:369-373

195. Tyler HR: Neurological complications of dialysis, transplantation, and other forms of treatment in chronic uremia. Neurology 1965;15:1081-1088

196. Teschan PE, Arieff AI: Uremic and dialysis encephalopathies. In McCandless DW (ed): Cerebral Energy Metabolism and Metabolic Encephalopathy. New York, Plenum, 1985, pp 263-2 5.

197. Sitprija V, Holmes JH: Preliminary observations on the changes in intracranial pressure and intraocular pressure during hemodialysis. Trans Am Soc Artif Intern Organs 1962;8:300-301.

198. Alfrey AC, Mishell JM, Burks J, et al: Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Transasaio 1972;18:257-265

199. Mahurkar SD, Dhar SK, Salta R, et al: Dialysis dementia. Lancet 1973;1:1412-1415

200. Alfrey AC, Le Gendre GR, Kaehny WD: The dialysis encephalopathy syndrome: Possible aluminum intoxication. n Engl J Med 1976; 294:184-188

201. Hainline B: Dialysis encephalopathy. In Feldmann E (ed): Current Diagnosis in Neurology. St. Louis, Mosby, 1994, pp 209-21 4.

202. Alfrey AC: The toxicity of the aluminum burden. Semin Nephrol 1983;3:329-334

203. Swartz RD: Deferoxamine and aluminum removal. Am J Kid Dis 1985;6:358-364

204. Van de Vyver FL, Silva FJE, D'Haese PC, et al: Aluminum toxicity in dialysis patients. Contrib Nephrol 1987;55:198-220

205. Ackrill P, Ralston AJ, Day JP, et al: Successful removal of aluminum from patients with dialytic encephalopathy. Lancet 1980;2:692-693

206. Chui HC, Damasio AR: Progressive dialysis encephalopathy ("dialysis dementia"). J Neurol 1980;222:145-157

207. Lederman RJ, Henry CE: Progressive dialysis encephalopathy. Ann Neurol 1978;4:199-204

208. Nadel AM, Wilson WP: Dialysis encephalopathy: A possible seizure disorder. Neurology 1976;26:1130-1134

209. Arieff AI: Metabolic encephalopathy: Uremia and dysmolar states. Course 231, Internal Medicine for the Neurologist II. 48th Annual Meeting of the American Academy of Neurology, San Francisco, 1996.

PreviousNext

Was this article helpful?

0 0
The Prevention and Treatment of Headaches

The Prevention and Treatment of Headaches

Are Constant Headaches Making Your Life Stressful? Discover Proven Methods For Eliminating Even The Most Powerful Of Headaches, It’s Easier Than You Think… Stop Chronic Migraine Pain and Tension Headaches From Destroying Your Life… Proven steps anyone can take to overcome even the worst chronic head pain…

Get My Free Audio Book


Post a comment